Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AEZS - COSCIENS Biopharma Inc.

15 minute delayed price
5.721
0.321   5.611%

Share volume: 7,563
Last Updated: Thu 08 Aug 2024 09:34:35 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$5.40
0.32
5.94%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 0%
Dept financing 24%
Liquidity 68%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.90%
1 Month
13.68%
3 Months
-32.75%
6 Months
-22.24%
1 Year
-52.96%
2 Year
-72.84%
Key data
Stock price
$5.72
P/E Ratio 
0.00
DAY RANGE
$5.48 - $6.20
EPS 
$0.00
52 WEEK RANGE
$3.96 - $12.00
52 WEEK CHANGE
-$0.55
MARKET CAP 
21.140 M
YIELD 
N/A
SHARES OUTSTANDING 
3.695 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,873
AVERAGE 30 VOLUME 
$4,994
Company detail
CEO: Klaus Paulini
Region: US
Website: http://www.aezsinc.com/
Employees: 47
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

æterna zentaris inc. (tsx: aez, nasdaq: aezs) is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. æterna zentaris inc. (tsx: aez, nasdaq: aezs) est une société biopharmaceutique internationale, spécialisée dans la découverte, le développement et la commercialisation de thérapies en endocrinologie et en oncologie.

Recent news